DEA unveils telehealth rules for Adderall, buprenorphine, other controlled medications - STAT
DEA has released new telehealth rules for prescribing controlled substances like Adderall and buprenorphine, potentially easing restrictions from the Ryan Haight Act but adding new compliance requirements.
Aforeworn detected this change in the Telehealth Cross-State Licensing space on July 22, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Telehealth platforms, virtual specialty clinics, behavioral-health providers, e-prescribers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Within 30 days of rule effective date (check publication date for exact deadline).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Telehealth Cross-State Licensing continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA now allows telehealth prescribing of controlled medications without an in-person visit, but requires special registration and adherence to new recordkeeping and reporting standards.
Who it affects
Telehealth platforms, virtual specialty clinics, behavioral-health providers, e-prescribers
What you must do
Review the new DEA rules and apply for special registration if prescribing controlled substances via telehealth; update compliance protocols.
Deadline
Within 30 days of rule effective date (check publication date for exact deadline).
Never miss a change like this again
Aforeworn watches Telehealth Cross-State Licensing around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Telehealth Cross-State Licensing
- Supreme court allows abortion pill mifepristone to continue to be available by mail - The Guardian
- Nevada Board Stuns Nonresident Pharmacists With New Requirements - Pharmacy Times
- DEA and HHS delay implementation of buprenorphine final rule | AHA News - American Hospital Association
- US-CONGRESS BILLS-119hr9790ih: Modernizing Opioid Treatment Access Act 2.0 of 2026
- Lawmakers say yes to prescribing opioids by telemedicine - New Hampshire Bulletin